Drug Description: Deoxyribonuclease (Desoxyribonucleasum)
Deoxyribonuclease is an enzyme found in the pancreas and intestinal mucosa; albumin-type protein. Hydrolyzes (depolymerizes) DNA to form deoxyribonucleotides.
For medical use, derived from the pancreas of cattle. It is a lyophilized white powder, soluble in water and isotonic sodium chloride solution; pH 0.1% aqueous solution 3, 0 - 5, 5. Aqueous solutions (and powder) are inactivated when heated above +55 'C.
Activity is determined by the formation of acid-soluble products released by the drug under certain conditions from DNA; it is expressed in units of activity (EA). In 1 mg of the drug should contain at least 1700 EA.
Drugs that are close to the action of deoxyribonuclease, are produced abroad under the names "Prenetic dornase", "Dornavac", etc.
Deoxyribonuclease has the ability to delay the development of herpes viruses, adenoviruses and other viruses containing DNA. The effect is associated with the depolymerization of DNA to mono - and oligonucleotides by cleavage of internucleotide bonds. By suppressing viral DNA synthesis, deoxyribonuclease does not damage the DNA of the microorganism cells.
Deoxyribonuclease also causes depolymerization and thinning of the pus.
Applied with herpetic keratitis and keratouvevity, adenoviral conjunctivitis and keratitis, lung abscesses, acute catarrhal inflammation of the upper respiratory tract adenoviral nature; to reduce viscosity and improve the evacuation of sputum and pus in case of bronchiectasis, lung abscesses, atelectasis, pneumonia; in the preoperative and postoperative periods in patients with purulent lung diseases, pulmonary tuberculosis.
For external use, deoxyribonuclease is used in the form of a 0.2% solution (2 mg of the drug in 1 ml) in an isotonic solution of sodium chloride. Solutions are prepared daily; shelf life of the solution - 12 hours
In case of herpetic keratitis and keratouveveitis, 0.5 ml of a sterile solution of deoxyribonuclease is administered daily under the conjunctiva of the affected eye for 2 to 4 weeks. In addition, 2 to 3 drops of a 0.2% solution are instilled into the eye 3 to 4 times a day. For the prevention of relapse, continue to administer the drug for 6 to 10 days after sustained clinical improvement.
For the treatment of adenoviral keratoconjunctivitis, 1 to 2 drops of a 0.05% solution in distilled water is introduced into the conjunctival cavity every 1.5 to 2 hours during the day.
In acute catarrhal inflammation of the upper respiratory tract of adenoviral nature, the solution is instilled into the nose or injected as an aerosol; inhalations of 10 to 15 minutes produce 2 to 3 times a day for 2 to 5 days. For each inhalation - 3 ml of 0.2% solution.
In the case of suppurative processes in the lungs, the solution is injected into the respiratory tract in the form of an aerosol at the rate of 1 ml of solution for 10-15 minutes.